Norway· NO-ID_4BD0A4CA-188E-41C8-A9BE-6BF29CB6233F

Bavencio

A avelumab product containing avelumab, registered in Norway by Merck Europe B.V.. The same ATC class is registered in 12 of our 19 countries.

ATC L01FF04

Checked against FEST (Norway) on

Informational only — not a medical device.

SOURCE REGISTER · NOFEST (Norway)normalisedBavencioATCL01FF04REGISTER NO.NO-ID_4BD0A4CA-188E-4…PACKS LISTED3CHECKEDSeptember 25, 2026

Where it is registered

Avelumab is registered in 12 of 19 countries.

Countries holding a registration under ATC L01FF04 (avelumab), each read from that country’s own register.

  • This record: Norway, from FEST (Norway)
  • 8 of them publish a price we can compare per daily dose

Avelumab · ATC L01FF04

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FEST (Norway)
Active substance
Avelumab
Manufacturer
Merck Europe B.V.
Country
Norway (NO)
ATC code
L01FF04
ATC class
Avelumab
Defined daily dose
57.1 mg, P
Reimbursed
Not published by this register
Source register
FEST (Norway)
Last checked
September 25, 2026

Packs & prices · 3

1 priced
  • no_merkevare_id
    ID_4BD0A4CA-188E-41C8-A9BE-6BF29CB6233F
  • gtin
    4054839415883
  • no_varenummer
    477913
    10
    NOK 11541

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

3 interactions on record for avelumab.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Avelumab · interactions on record

3 records

  • 3 severe

Most severe, free to view

  • ThalidomideL04AX02severe
  • LenalidomideL04AX04severe
  • PomalidomideL04AX06severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Avelumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All avelumab products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Iceland · Bavencio
  • Liechtenstein · Bavencio

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/3808673f-f37b-4b77-a837-32dd7207e214
GET /v1/drugs/3808673f-f37b-4b77-a837-32dd7207e214?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Konsentrat til infusjonsvæske, oppløsning",
  "source": "fest",
  "status": "A",
  "atc_name": "Avelumab",
  "merkevare_id": "ID_4BD0A4CA-188E-41C8-A9BE-6BF29CB6233F",
  "name_form_strength": "Bavencio kons til inf oppl 20 mg/ml",
  "prescription_group": "C"
}

See everything about avelumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.